Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.05
    +1.70 (+2.09%)
     
  • Gold

    2,240.70
    +28.00 (+1.27%)
     
  • Silver

    24.98
    +0.23 (+0.92%)
     
  • EUR/USD

    1.0791
    -0.0039 (-0.36%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2624
    -0.0014 (-0.11%)
     
  • USD/JPY

    151.3750
    +0.1290 (+0.09%)
     
  • Bitcoin USD

    70,756.98
    +1,825.64 (+2.65%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients

  • Veru Inc (NASDAQ: VERU) has announced that the Phase 2 results evaluating enobosarm for breast cancer include further efficacy data and an analysis of patients who have failed estrogen blocking agents and CDK 4/6 inhibitors.

  • Data will be presented at the European Society for Medical Oncology Breast Cancer Virtual Congress 2021.

  • The subset of patients includes those who were heavily pretreated with estrogen-blocking agents and chemotherapy with an average of 3 prior lines of therapy in the metastatic setting and had tumor progression on a CDK 4/6 inhibitor before receiving enobosarm.

  • Enobosarm treatment in evaluable patients who had progressed following treatment with an estrogen-blocking agent and CDK 4/6 inhibitor (palbociclib) resulted in a clinical benefit rate at 24 weeks of 50% and a best objective tumor response of 30%, including two complete responses and one partial response.

  • The overall mean radiographic progression-free survival for the 9mg dose was ten months.

  • The 9mg dose of enobosarm was selected for the Phase 3 ARTEST study anticipated to start in June.

  • Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor targeting agonist that activates the androgen receptor, tumor suppressor, in AR+ER+HER2- metastatic breast cancer.

  • Price Action: VERU stock moved 26.4% higher at $11 during the premarket trading session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement